C-reactive protein and the biology of disease
The C-reactive protein (CRP) is a plasma protein of hepatic origin, belonging to pentraxin family and forms a major component of any inflammatory reaction. A key component of the innate immunity pathway, the concentration of CRP may rapidly increase to levels more than 1,000-folds above normal values as a consequence to tissue injury or infection. Although functioning as a classical mediator of innate immunity, it functions via interaction of components of both humoral and cellular effector systems of inflammation. Initially considered as an acute-phase marker in tissue injury, infection and inflammation, it now has a distinct status of a disease marker in cardiovascular diseases and is well known of its clinical and pathological significance. The present torrent of studies in a large number of diseases and associated conditions has highly elucidated the role of CRP as a therapeutic and research reagent. In this review, we focus our attention to role of CRP in health and disease. The future prospect of this review lies in the applicability of CRP as a molecule in understanding and monitoring of the biology of disease.
KeywordsC-reactive protein Disease Inflammation
Both authors express gratitude to the Institutions School of Biological sciences, NISER, Bhubaneswar and Asutosh College, Kolkata for providing the infrastructure for the study. They express their gratitude to Dr. Chitra Mandal, outstanding Scientist, Indian Institute of Chemical Biology, CSIR, India for her guidance and support during their Ph.D.
Conflict of interest
The authors declare no conflict of interest.
- 3.Abernethy TJ, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. 1. Distribution of the reactive protein in patient’s sera and the effect of calcium on the flocculation reaction with C polysaccharide of Pneumococcus. J Exp Med. 1941;73:173–82.PubMedCrossRefGoogle Scholar
- 48.Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.Google Scholar
- 55.Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995;332:635–41.PubMedCrossRefGoogle Scholar
- 56.Tanigaki K, Vongpatanasin W, Barrera JA, Atochin DN, Huang PL, Bonvini E, et al. C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB-mediated inhibition of skeletal muscle glucose delivery. Diabetes. 15 Oct 2012. [in press].Google Scholar
- 65.Dongho Dongmo FF, Ngono Ngane RA, Gouado I, Pankoui Mfonkeu JB, Mbackop Kwemba V, et al. Predictors of childhood severe malaria in a densely populated area: Douala, Cameroon. Afr J Biotechnol. 2011;10:6319–24.Google Scholar
- 67.Bourée P, Botterel F, Lançon A. Comparative study VS-CRP in malaria. Mal. Inf. Dis. Afr. 2000;2–3.Google Scholar
- 68.Kremsner PG, Winkler S, Wildling E, Prada J, Bienzlz U, Graninger W, Nüssler AK. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitogical and clinical cure in Plasmodium falciparum malaria. Trans R Trop Med Hyg. 1996;90:44–7.CrossRefGoogle Scholar
- 79.Ansar W, Mukhopadhyay S, Habib SK, Basu S, Saha B, Sen AK, et al. Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J. 2009;26:1151–69.PubMedCrossRefGoogle Scholar